Also published in Send Press Releases with GlobeNewswire:
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
x hide permanently

Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates

Send Press Releases with GlobeNewswire

Photo: Pixabay

CytoDyn Inc., a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the publication in Nature Communications of a study showing leronlimab prevented nonhuman primates from being infected with Simian Human Immunodeficiency virus (SHIV), a monkey-human chimeric form of HIV. The results will inform a future human clinical trial evaluating leronlimab as a potential pre-exposure prophylaxis, or PrEP, therapy to prevent human infection from the virus that causes AIDs. “Antibody-based CCR5 Blockade Protects Macaques from Mucosal SHIV Transmission” can be found at:

“Our study ...